On June 12, 2024, Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a multi-year data license agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular, and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. This license agreement includes data to be generated from single-cell sequencing to study cell populations in perfused human livers, as well as data generated from large-scale gene perturbation in human liver cells. The deal has a total value of up to $37.5 million for both co-exclusive and non-exclusive data licenses.

The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK’s disease area focus in hepatology, with the aim to further prioritize and accelerate development of medicines to address liver disease. The data will be used by both Ochre Bio and GSK to build better AI models, allowing for fewer, but more precise experiments to aid in target choice.

Wilson Sonsini Goodrich & Rosati represented Ochre Bio in the agreement. The Wilson Sonsini team includes:

Technology Transactions
Farah Gerdes
Nellie Brutocao
Andrew Poling

Privacy and Cybersecurity
Nikolaos Theodorakis
Demian Ahn
Hale Melnick

Tax
Sarah Lane
Myra Sutanto Shen

Patents and Innovations
Lou Lieto

For more information, please see Ochre Bio’s press release.